Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Slightly above 62% of Orgenesis' investor base is looking to short. The analysis of overall sentiment of trading Orgenesis otc stock suggests that many investors are alarmed at this time. Orgenesis' investing sentiment can be driven by a variety of factors including economic data, Orgenesis' earnings reports, geopolitical events, and overall market trends.
Orgenesis otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Orgenesis daily returns and investor perception about the current price of Orgenesis as well as its diversification or hedging effects on your existing portfolios.
Orgenesis |
GERMANTOWN, Md., Nov. 14, 2023 -- Orgenesis Inc. , a global biotech company working to unlock the full potential of cell and gene therapies , today announced it ranked 171 on the Deloitte Technology Fast 500, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Vered Caplan, CEO of Orgenesis, commented, We are very proud
Read at finance.yahoo.com
Orgenesis Fundamental Analysis
We analyze Orgenesis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Orgenesis is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Orgenesis Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Orgenesis otc stock to make a market-neutral strategy. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics with similar companies.
Peers
Orgenesis Related Equities
ACRV | Acrivon Therapeutics, | 11.28 | ||||
LIXT | Lixte Biotechnology | 9.36 | ||||
KTTA | Pasithea Therapeutics | 6.78 | ||||
RZLT | Rezolute | 5.10 | ||||
ADAG | Adagene | 3.52 | ||||
QNRX | Quoin Pharmaceuticals | 3.08 | ||||
TNGX | Tango Therapeutics | 1.29 | ||||
INDP | Indaptus Therapeutics | 1.19 | ||||
ANTX | AN2 Therapeutics | 0.72 | ||||
NRBO | Neurobo Pharmaceuticals | 0.00 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
DSGN | Design Therapeutics | 1.28 | ||||
ACHL | Achilles Therapeutics | 3.39 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |